Indomethacin and SC236 enhance the cytotoxicity of doxorubicin in human hepatocellular carcinoma cells via inhibiting P-glycoprotein and MRP1 expression

Cancer Letters

Volumn 304, Issue 2, 2011, Pages 90-96

  Ye, Cai Guo ^a,b   Wu, William Ka Kei ^a   Yeung, John Hok Keung ^a   Li, Hai Tao ^a   Li, Zhi Jie ^a   Wong, Clover Ching Man ^a   Ren, Shun Xiang ^a   Zhang, Lin ^a   Fung, Kwok Pui ^a   Cho, Chi Hin ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2 selective inhibitor; Hepatocellular carcinoma; MRP1; P glycoprotein

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; DOXORUBICIN; GLYCOPROTEIN P; INDOMETACIN; MULTIDRUG RESISTANCE PROTEIN 1; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE;

ARTICLE; CANCER RESISTANCE; CELL LEVEL; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG RETENTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SEPARATION; CYCLOOXYGENASE 2 INHIBITORS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLOW CYTOMETRY; HUMANS; INDOMETHACIN; LIVER NEOPLASMS; MICROSCOPY, CONFOCAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PYRAZOLES; SULFONAMIDES;

EID: 79952737788     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.025     Document Type: Article

References (24)

1. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
2. Turk D., Szakacs G. Relevance of multidrug resistance in the age of targeted therapy. Curr. Opin. Drug. Discov. Devel. 2009, 12:246-252.
3. Tainton K.M., Smyth M.J., Jackson J.T., Tanner J.E., Cerruti L., Jane S.M., Darcy P.K., Johnstone R.W. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ. 2004, 11:1028-1037.
4. Mimeault M., Hauke R., Batra S.K. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin. Pharmacol. Ther. 2008, 83:673-691.
5. Sanchez C., Mendoza P., Contreras H.R., Vergara J., McCubrey J.A., Huidobro C., Castellon E.A. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 2009, 69:1448-1459.
6. de Groot D.J., van der Deen M., Le T.K., Regeling A., de Jong S., de Vries E.G. Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1. Brit. J. Cancer. 2007, 97:1077-1083.
7. Souza R.F., Shewmake K., Beer D.G., Cryer B., Spechler S.J. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 2000, 60:5767-5772.
8. Hanif R., Pittas A., Feng Y., Koutsos M.I., Qiao L., Staiano-Coico L., Shiff S.I., Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. 1996, 52:237-245.
9. Patel V.A., Dunn M.J., Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem. 2002, 277:38915-38920.
10. Fantappie O., Solazzo M., Lasagna N., Platini F., Tessitore L., Mazzanti R. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res. 2007, 67:4915-4923.
11. Roy K.R., Reddy G.V., Maitreyi L., Agarwal S., Achari C., Vali S., Reddanna P. Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother. Pharmacol. 2010, 65:903-911.
12. Yu L., Wu W.K., Li Z.J., Liu Q.C., Li H.T., Wu Y.C., Cho C.H. Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonami de (SC236) via inhibiting P-glycoprotein activity. Mol. Pharmacol. 2009, 75:1364-1373.
13. Trevisani F., Cantarini M.C., Wands J.R., Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 2008, 29:1299-1305.
14. Llovet J.M., Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008, 48:1312-1327.
15. Beck J.F., Buchholz F., Ulrich W.R., Boer R., Sanders K.H., Niethammer D., Gekeler V. Rhodamine 123 efflux modulation in the presence of low or high serum from CD56+ hematopoietic cells or CD34+ leukemic blasts by B9309-068, a newly designed pyridine derivative. Cancer Lett. 1998, 129:157-163.
16. Evers R., Kool M., Smith A.J., van Deemter L., de Haas M., Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Brit. J. Cancer 2000, 83:366-374.
17. Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993, 53:4595-4602.
18. Duffy C.P., Elliott C.J., O'Connor R.A., Heenan M.M., Coyle S., Cleary I.M., Kavanagh K., Verhaegen S., O'Loughlin C.M., NicAmhlaoibh R., Clynes M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer 1998, 34:1250-1259.
19. Pascolo L., Fernetti C., Pirulli D., Bogoni S., Garcia-Mediavilla M.V., Spano A., Puzzer D., Tiribelli C., Amoroso A., Crovella S. Detection of MRP1 mRNA in human tumors and tumor cell lines by in situ RT-PCR. Biochem. Biophys. Res. Commun. 2000, 275:466-471.
20. Zrieki A., Farinotti R., Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. 2008, 25:1991-2001.
21. Puhlmann U., Ziemann C., Ruedell G., Vorwerk H., Schaefer D., Langebrake C., Schuermann P., Creutzig U., Reinhardt D. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J. Pharmacol. Exp. Ther. 2005, 312:346-354.
22. Kang H.K., Lee E., Pyo H., Lim S.J. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol. Cancer Ther. 2005, 4:1358-1363.
23. van Brussel J.P., van Steenbrugge G.J., Romijn J.C., Schroder F.H., Mickisch G.H. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins. Eur. J. Cancer 1999, 35:664-671.
24. Sullivan G.F., Yang J.M., Vassil A., Yang J., Bash-Babula J., Hait W.N. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J. Clin. Invest. 2000, 105:1261-1267.